Aliases & Classifications for Uremia

MalaCards integrated aliases for Uremia:

Name: Uremia 12 72 51 41 14 69
Uremia of Renal Origin 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4676
ICD10 32 N19
MeSH 41 D014511
UMLS 69 C0041948

Summaries for Uremia

MalaCards based summary : Uremia, also known as uremia of renal origin, is related to peritonitis and hyperphosphatemia. An important gene associated with Uremia is EPO (Erythropoietin), and among its related pathways/superpathways are HIF-1 signaling pathway and Adipogenesis. The drugs Fexofenadine and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and endothelial, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 72 Uremia is the condition of having \"urea in the blood\". Urea is one of the primary components of urine.... more...

Related Diseases for Uremia

Diseases related to Uremia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
# Related Disease Score Top Affiliating Genes
1 peritonitis 30.5 ALB B2M CRP
2 hyperphosphatemia 30.2 CASR PTH VDR
3 hyperparathyroidism 30.2 CASR EPO PTH TNFRSF11B VDR
4 renal osteodystrophy 30.0 CASR PTH TNFRSF11B VDR
5 autonomic neuropathy 29.9 ALB EPO INS
6 secondary hyperparathyroidism of renal origin 29.8 ALB CASR EPO PTH TNFRSF11B VDR
7 arteriosclerosis 29.8 CRP INS SPP1
8 multiple endocrine neoplasia, type i 29.7 CASR INS PTH
9 sleep apnea 29.7 CRP INS LEP
10 arteries, anomalies of 29.6 ALB CRP INS LEP VWF
11 primary hyperparathyroidism 29.5 ALB CASR PTH VDR
12 insulin-like growth factor i 29.4 GHR INS LEP
13 pancreatitis 29.4 CASR CRP LPL
14 kidney disease 29.3 ALB B2M CASR EPO PTH TF
15 liver disease 29.1 ALB INS LEP TF
16 hypertriglyceridemia, familial 29.0 APOC3 INS LPL
17 coronary heart disease 1 28.8 APOC3 CRP INS LPL
18 vascular disease 28.7 CRP INS LPL RETN TNFRSF11B VWF
19 coronary artery anomaly 28.6 APOC3 CRP INS LPL RETN
20 hypertension, essential 28.1 ALB CRP INS LEP LPL RETN
21 myocardial infarction 28.1 ALB APOC3 CRP INS RETN VWF
22 chronic kidney failure 28.0 ALB B2M CASR CRP EPO INS
23 body mass index quantitative trait locus 11 26.7 AHSG APOC3 CRP GHR INS LEP
24 nephronophthisis 1 11.0
25 hemolytic-uremic syndrome 10.9
26 euthyroid sick syndrome 10.9
27 autosomal dominant tubulointerstitial kidney disease 10.9
28 malignant otitis externa 10.6 CRP INS
29 immunodeficiency 43 10.5 ALB B2M
30 scleredema adultorum 10.5 INS PTH
31 fetal erythroblastosis 10.5 ALB EPO INS
32 fibrogenesis imperfecta ossium 10.5 PTH TNFRSF11B
33 pyuria 10.5 ALB CRP
34 fanconi-like syndrome 10.4 B2M CASR
35 orthostatic proteinuria 10.4 ALB B2M
36 miliary tuberculosis 10.4 CRP EPO
37 burns 10.4 ALB INS
38 hemorrhagic fever with renal syndrome 10.4 ALB B2M CRP
39 uremic neuropathy 10.4 B2M EPO PTH
40 carotid stenosis 10.4 CRP SPP1 TNFRSF11B
41 intermittent claudication 10.3 ALB CRP VWF
42 gastrointestinal system disease 10.3 ALB CRP INS
43 acquired immunodeficiency syndrome 10.3 ALB B2M EPO
44 coronary stenosis 10.3 ALB CRP VWF
45 lipodystrophy, familial partial, type 2 10.3 INS LEP
46 xanthinuria, type i 10.3 CASR SPP1 VDR
47 nephrolithiasis, calcium oxalate 10.3 CASR SPP1 VDR
48 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.3 CRP INS LEP
49 diabetic angiopathy 10.3 INS TNFRSF11B VWF
50 hypercalcemia, infantile, 1 10.3 CASR PTH VDR

Graphical network of the top 20 diseases related to Uremia:



Diseases related to Uremia

Symptoms & Phenotypes for Uremia

MGI Mouse Phenotypes related to Uremia:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 LPL INS PTH LEP RETN SPP1
2 cellular MP:0005384 10.34 LPL INS PTH LEP SPP1 ALB
3 cardiovascular system MP:0005385 10.31 LPL INS PTH LEP SPP1 CRP
4 growth/size/body region MP:0005378 10.27 LPL INS PTH LEP GHR CASR
5 hematopoietic system MP:0005397 10.26 INS PTH LEP GHR CASR EPO
6 immune system MP:0005387 10.25 INS PTH LEP RETN SPP1 CRP
7 mortality/aging MP:0010768 10.1 LPL INS PTH LEP CASR ALB
8 integument MP:0010771 10.06 LPL INS LEP GHR CASR EPO
9 digestive/alimentary MP:0005381 10.05 INS LEP CASR ALB B2M VDR
10 liver/biliary system MP:0005370 9.97 LPL INS RETN LEP ALB EPO
11 limbs/digits/tail MP:0005371 9.91 PTH LEP GHR AHSG EPO VDR
12 muscle MP:0005369 9.85 LPL INS LEP SPP1 AHSG ALB
13 renal/urinary system MP:0005367 9.5 GHR INS LEP CASR ALB VDR
14 skeleton MP:0005390 9.32 INS PTH LEP GHR CASR AHSG

Drugs & Therapeutics for Uremia

Drugs for Uremia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
2
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
3
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
6
Metformin Approved Phase 4 657-24-9 4091 14219
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Pamidronate Approved Phase 4 40391-99-9 4674
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
12
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
13 Tocopherol Approved, Investigational, Nutraceutical Phase 4
14
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
15 tannic acid Approved, Nutraceutical Phase 4
16 Analgesics Phase 4,Phase 3
17 Anti-Allergic Agents Phase 4
18 Anti-Anxiety Agents Phase 4
19 Anticonvulsants Phase 4
20 calcium channel blockers Phase 4
21 Calcium, Dietary Phase 4
22 Central Nervous System Depressants Phase 4
23 Histamine Antagonists Phase 4
24 Histamine H1 Antagonists Phase 4
25 Histamine H1 Antagonists, Non-Sedating Phase 4
26
Histamine Phosphate Phase 4 51-74-1 65513
27 Neurotransmitter Agents Phase 4
28 Peripheral Nervous System Agents Phase 4,Phase 3
29 Psychotropic Drugs Phase 4
30 Tranquilizing Agents Phase 4
31 Hormone Antagonists Phase 4,Phase 2
32 Hormones Phase 4,Phase 2
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
35 Hematinics Phase 4
36 Micronutrients Phase 4,Phase 2
37 Trace Elements Phase 4,Phase 2
38 Vitamin B Complex Phase 4
39 Vitamins Phase 4,Phase 2
40 Antioxidants Phase 4,Phase 1,Phase 2
41 Protective Agents Phase 4,Phase 1,Phase 2
42 Polymethyl Methacrylate Phase 4
43 Vasodilator Agents Phase 4
44 Tocopherols Phase 4
45 Tocotrienols Phase 4
46 Hypoglycemic Agents Phase 4,Phase 2
47 Incretins Phase 4
48 Dialysis Solutions Phase 4,Phase 3,Phase 2
49 Folate Nutraceutical Phase 4
50 Vitamin B9 Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 102)

# Name Status NCT ID Phase Drugs
1 Probiotics Use in the Chronic Peritoneal Dialysis Patients Unknown status NCT01076426 Phase 4 Pro-biotics
2 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
3 Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events Completed NCT00317005 Phase 4 folate treatment
4 Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients Completed NCT01356433 Phase 4 oral vitamin C;oral vitamin C
5 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
6 Oxidative Stress and Hemodialysis Access Failure Completed NCT00410449 Phase 4 Alpha tocopherol
7 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease Completed NCT00513630 Phase 4 Glipizide;Metformin
8 Heat Disinfection of HD Water Treatment System in Hemodialysis Patients Completed NCT01138280 Phase 4
9 Hannover Dialysis Outcome Study Completed NCT00529139 Phase 4
10 Very Low Protein Diet or Dialysis in Uremic Elderly? Completed NCT00388648 Phase 4 mixture of amino and keto acids
11 A Clinical Trial of IntensiVE Dialysis Completed NCT00649298 Phase 4
12 Liraglutide Treatment to Patients With Severe Renal Insufficiency Completed NCT01394341 Phase 4 Liraglutide
13 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
14 STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE Completed NCT00278057 Phase 4 dialysisis with and without glucose in the dialysis
15 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
16 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
17 Nafamostat Efficacy and Safety in Critically Ill Patients(NICE) Unknown status NCT01486485 Phase 3 heparinized saline priming group;nafamostat infusion after heparinized saline priming
18 The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients Completed NCT02747979 Phase 2, Phase 3
19 Effects of Convective Therapies in Dialysis Patients Completed NCT01583309 Phase 3
20 Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Completed NCT01410916 Phase 2, Phase 3 Eculizumab (Soliris®)
21 Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Recruiting NCT03205995 Phase 3
22 Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT03131219 Phase 3
23 Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT02949128 Phase 3
24 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Recruiting NCT02205541 Phase 3 Eculizumab;Placebo
25 Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis Not yet recruiting NCT02976688 Phase 2, Phase 3
26 Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome Terminated NCT00004465 Phase 3 SYNSORB Pk;Placebo
27 The Plasma Large-Volume Exchange RCT Withdrawn NCT01433003 Phase 3
28 Effect of SVF Derived MSC in DCD Renal Transplantation Unknown status NCT02492490 Phase 1, Phase 2 Basiliximab
29 Clonal Deletion on Living-Relative Donor Kidney Transplantation Unknown status NCT01408797 Phase 1, Phase 2 MMF, Bortezomib
30 Effect of BM-MSCs in DCD Kidney Transplantation Unknown status NCT02561767 Phase 1, Phase 2 Induction therapy (ATG or Basiliximab);Maintenance therapy (Low-dose CNI + MPA + steroids)
31 Treatment of Uremic Pruritus by Olive-omega 3 Ointment Unknown status NCT01447693 Phase 1, Phase 2
32 Induction With SVF Derived MSC in Living-related Kidney Transplantation Unknown status NCT02492308 Phase 1, Phase 2 Basiliximab induction
33 Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Unknown status NCT01876017 Phase 1, Phase 2
34 Rituximab in Patients With Relapsed or Refractory TTP-HUS Unknown status NCT00531089 Phase 2 Rituximab
35 L-Cysteine in Peritoneal Dialysis Completed NCT02050139 Phase 2
36 Clinical and Biochemical Effects of Multipass Hemodialysis Completed NCT01267760 Phase 2
37 Omega-3 Fatty Acid Administration in Dialysis Patients Completed NCT00655525 Phase 2
38 Vitamin D, Insulin Resistance and Inflammation in ESRD Completed NCT00656032 Phase 2
39 Role of Turmeric on Oxidative Modulation in ESRD Patients Completed NCT01906840 Phase 1, Phase 2 Turmeric;placebo
40 Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome Completed NCT00309257 Phase 2 ACE I, ATA II and Statins;Benazepril, Valsartan and Fluvastatin
41 Sevelamer in Proteinuric CKD Completed NCT01968759 Phase 2 Sevelamer;Ramipril and Irbesartan
42 A Study in Patients With End-Stage Renal Disease Completed NCT01200290 Phase 2 LY2127399
43 The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT01757431 Phase 2 Eculizumab
44 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Completed NCT01194973 Phase 2 Eculizumab
45 An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Completed NCT01193348 Phase 2 Eculizumab
46 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Completed NCT00844844 Phase 2 Eculizumab
47 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Completed NCT00844545 Phase 2 Eculizumab
48 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Completed NCT00844428 Phase 2 eculizumab
49 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT00838513 Phase 2 eculizumab
50 A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Recruiting NCT03303313 Phase 2 Cemdisiran

Search NIH Clinical Center for Uremia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: uremia

Genetic Tests for Uremia

Anatomical Context for Uremia

MalaCards organs/tissues related to Uremia:

38
Kidney, Testes, Endothelial, Bone, Monocytes, Liver, Neutrophil

Publications for Uremia

Articles related to Uremia:

(show top 50) (show all 706)
# Title Authors Year
1
Uremia: A historical reappraisal of what happeneda8c. ( 29451473 )
2018
2
Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification. ( 29304096 )
2018
3
CRP, ILa892 and TNFa89I+ level in patients with uremia receiving hemodialysis. ( 29257244 )
2018
4
Uremia modulates the phenotype of aortic smooth muscle cells. ( 28107707 )
2017
5
The Evolving Patterns of Uremia: Unmet Clinical Needs in Dialysis. ( 28910786 )
2017
6
Proceedings of the Ninth International Congress of Uremia Research and Toxicity. ( 29056162 )
2017
7
Influence of SPK with Enteric Drainage on the Pancreatic Exocrine Function in Diabetic Patients with Uremia. ( 29138633 )
2017
8
Uremia ( 28722889 )
2017
9
Risk factors for cardiovascular disease in children on chronic hemodialysis - Uremia related (non-traditional) risk factors, part II. ( 29350892 )
2017
10
Uremia induces adipose tissue inflammation and muscle mitochondrial dysfunction. ( 28605780 )
2017
11
Relationship between serum total bilirubin levels and mortality in uremia patients undergoing long-term hemodialysis: A nationwide cohort study. ( 28892712 )
2017
12
Uremia Retention Molecules and Clinical Outcomes. ( 28910788 )
2017
13
The function of the parathyroid oxyphil cells in uremia: still aA mystery? ( 29055426 )
2017
14
Skin Blood Flow and Vascular Endothelium Function in Uremia. ( 29056167 )
2017
15
Uremia does not affect neointima formation in mice. ( 28747676 )
2017
16
CORRIGENDUM: Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 28832560 )
2017
17
Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 29040261 )
2017
18
Serpiginous cranial arterial calcification in uremia. ( 28972106 )
2017
19
Research progress about effects of myocardial enzyme and troponin on uremia with acute left ventricular failure. ( 28338189 )
2017
20
A History of Uremia Research. ( 29056163 )
2017
21
Sudden bilateral vision loss as the sole manifestation of posterior reversible encephalopathy syndrome from acute uremia: Clinical case report. ( 28682904 )
2017
22
Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 28376076 )
2017
23
"Uremic Toxin" Section in the Journal Toxins: A Powerful Tool to Bundle and Advance Knowledge on Uremia. ( 28524108 )
2017
24
Persistence of Vascular Calcification after Reversal of Uremia. ( 27939134 )
2017
25
Evaluation of the different surgical parathyroidectomieson secondary hyperparathyroidism in uremia patients. ( 29205012 )
2017
26
Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. ( 28341272 )
2017
27
Bilateral rectal sheath hematomas after low-molecular weight heparin treatment in uremia. ( 28330422 )
2017
28
Increased Neutrophil Extracellular Trap Formation in Uremia Is Associated with Chronic Inflammation and Prevalent Coronary Artery Disease. ( 28523279 )
2017
29
Simultaneous liver, pancreas-duodenum and kidney transplantation in a patient with hepatitis B cirrhosis, uremia and insulin dependent diabetes mellitus. ( 29259387 )
2017
30
Co-Expression Analysis of Blood Cell Genome Expression to Preliminary Investigation of Regulatory Mechanisms in Uremia. ( 28050009 )
2017
31
Asymptomatic Brain Edema after Hemodialysis Initiation in a Patient with Severe Uremia. ( 28553356 )
2017
32
ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis. ( 28351665 )
2017
33
Electronegative low-density lipoprotein increases the risk of ischemic lower-extremity peripheral artery disease in uremia patients on maintenance hemodialysis. ( 28680087 )
2017
34
Aphasic Status Epilepticus Associated with Uremia. ( 29344470 )
2017
35
A Comparison between Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Eradication in Patients with Uremia: A Randomized Clinical Trial. ( 26933480 )
2016
36
Electronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance Hemodialysis. ( 26765403 )
2016
37
MRI Findings of Syndrome of Acute Bilateral Symmetrical Basal Ganglia Lesions in Diabetic Uremia: A Case Report and Literature Review. ( 27493824 )
2016
38
Sweating in Systemic Abnormalities: Uremia and Diabetes Mellitus. ( 27584963 )
2016
39
Lion face in a uremia patient. ( 28011855 )
2016
40
Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. ( 26831434 )
2016
41
DNA methylation profiling reveals differences in the 3 human monocyte subsets and identifies uremia to induce DNA methylation changes during differentiation. ( 27018948 )
2016
42
Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis. ( 26988587 )
2016
43
Myocardial bioenergetic abnormalities in experimental uremia. ( 27307758 )
2016
44
Ptosis and uremia as a rare feature of uremia. ( 27728481 )
2016
45
Uremia-Associated Premature Ageing Of T Cells Does Not Predict Infectious Complications After Renal Transplantation. ( 26914971 )
2016
46
Urea transporters and sweat response to uremia. ( 27273880 )
2016
47
Vascular Calcification in Uremia: New-Age Concepts about an Old-Age Problem. ( 26676134 )
2016
48
Comparison of HLA-A, -B and -DRB1 Loci Polymorphism between Kidney Transplants of Uremia Patients and Healthy Individuals in Central China. ( 27780235 )
2016
49
Development of Acute Pericarditis Associated with New-onset Rheumatoid Arthritis in a Diabetic Patient with Renal Impairment: The Elusive Nature of Uremia. ( 27086811 )
2016
50
Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis. ( 27992874 )
2016

Variations for Uremia

Expression for Uremia

Search GEO for disease gene expression data for Uremia.

Pathways for Uremia

GO Terms for Uremia

Cellular components related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 AHSG ALB APOC3 B2M CRP EPO
2 cell surface GO:0009986 9.73 B2M CASR EPO GHR LPL TF
3 secretory granule lumen GO:0034774 9.63 AHSG INS TF
4 endoplasmic reticulum lumen GO:0005788 9.63 AHSG ALB B2M INS SPP1 TF
5 platelet alpha granule lumen GO:0031093 9.58 AHSG ALB VWF
6 extracellular space GO:0005615 9.5 AHSG ALB APOC3 B2M CRP EPO
7 chylomicron GO:0042627 9.43 APOC3 LPL
8 HFE-transferrin receptor complex GO:1990712 9.37 B2M TF
9 extracellular exosome GO:0070062 10.02 AHSG ALB APOC3 B2M CRP LPL

Biological processes related to Uremia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.91 B2M LPL PTH TNFRSF11B
2 cellular calcium ion homeostasis GO:0006874 9.73 CASR PTH VDR
3 response to nutrient GO:0007584 9.71 EPO LEP TNFRSF11B
4 regulation of receptor activity GO:0010469 9.7 EPO INS LEP PTH RETN SPP1
5 skeletal system development GO:0001501 9.67 AHSG PTH TNFRSF11B VDR
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 EPO GHR LEP
7 high-density lipoprotein particle remodeling GO:0034375 9.6 ALB APOC3
8 negative regulation of lipid catabolic process GO:0050995 9.59 APOC3 INS
9 iron ion transport GO:0006826 9.58 B2M TF
10 intestinal absorption GO:0050892 9.58 LEP VDR
11 positive regulation of glycogen biosynthetic process GO:0045725 9.57 INS PTH
12 platelet degranulation GO:0002576 9.56 AHSG ALB TF VWF
13 positive regulation of insulin receptor signaling pathway GO:0046628 9.55 INS LEP
14 negative regulation of blood vessel diameter GO:0097756 9.52 CRP INS
15 negative regulation of lipid storage GO:0010888 9.51 CRP LEP
16 retina homeostasis GO:0001895 9.5 ALB B2M TF
17 chylomicron remodeling GO:0034371 9.49 APOC3 LPL
18 response to fibroblast growth factor GO:0071774 9.46 CASR PTH
19 cellular response to iron ion GO:0071281 9.43 B2M TF
20 negative regulation of feeding behavior GO:2000252 9.4 INS RETN
21 acute-phase response GO:0006953 9.26 AHSG CRP EPO INS
22 cellular protein metabolic process GO:0044267 9.1 AHSG ALB B2M INS SPP1 TF

Molecular functions related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ALB B2M CRP GHR INS VWF
2 hormone activity GO:0005179 9.02 EPO INS LEP PTH RETN
3 peptide hormone receptor binding GO:0051428 8.96 LEP PTH

Sources for Uremia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....